FDA:Daraxonrasib and the Expansion of RAS-Targeted Therapy

Clinical Breakthrough, Regulatory Extrapolation, and the Opportunity Cost of a Broad FDA Label

BBIU Strategic Report | September 2026

Executive Summary

The FDA approval of RASONQUE™ (daraxonrasib) represents a genuine therapeutic and pharmacologic advance. It is the first approved oral RAS(ON) multi-selective inhibitor and the first broadly RAS-targeted medicine for metastatic pancreatic adenocarcinoma. In the 500-patient Phase 3 RASolute 302 trial, daraxonrasib produced a large survival benefit over investigator-selected chemotherapy in previously treated disease: median overall survival increased from 6.7 to 13.2 months, while median progression-free survival increased from 3.6 to 7.2 months. The hazard ratio for death was 0.40.

The central analytical issue is therefore not whether daraxonrasib demonstrated efficacy. It did. The unresolved question is how evidence generated predominantly in previously treated patients with RAS G12-mutated tumors supported an FDA indication that:

• Does not require confirmation of a RAS mutation or a companion diagnostic.

• Includes patients who are not candidates for multiagent systemic therapy, potentially permitting use before any previous treatment for metastatic disease.

The distinction matters because 459 of the trial's 500 patients—91.8%—had RAS G12 mutations, and the dual primary endpoints were formally tested in that population. Only 41 patients fell outside RAS G12. In this small, molecularly heterogeneous subgroup, overall survival favored daraxonrasib, but progression-free survival numerically favored chemotherapy. The overall-population analysis consequently does not provide evidence independent of the RAS G12 population; it is numerically dominated by it.

A second external-validity problem concerns treatment line and fitness. RASolute 302 enrolled patients with ECOG performance status 0–1 who had already experienced progression after systemic therapy for metastatic disease or rapid metastatic recurrence after perioperative treatment. It did not directly randomize newly diagnosed, treatment-naive, clinically frail patients considered unable to receive multiagent therapy.

A third interpretive issue arose after randomization. Treatment was initiated by 97.2% of patients assigned to daraxonrasib but only 84.9% of those assigned to chemotherapy. Twenty-nine control patients withdrew before beginning chemotherapy, compared with one patient assigned to daraxonrasib. The intention-to-treat analysis remains the correct primary analysis, but the asymmetry creates a treatment-policy question: part of the observed result may reflect assignment to an attractive oral targeted therapy versus assignment to chemotherapy that some patients declined, rather than the pharmacologic contrast alone.

The economic implications are equally consequential. RASONQUE launched at a wholesale acquisition cost of USD 39,800 per 30-day supply. Applying the 6.2-month median treatment duration observed in RASolute 302 produces an estimated gross acquisition cost of approximately USD 246,760 per treated patient. Simple median-based screening calculations yield approximately USD 68,500 per additional median progression-free month and USD 455,600 per median life-year proxy. These are not formal incremental cost-effectiveness ratios: valid economic modeling requires mean survival, utilities, complete cost data, and extrapolation of the full survival curves.

Daraxonrasib may reduce infusion, hematologic-toxicity, hospitalization, and patient-time costs compared with chemotherapy. It also delayed deterioration in pain and global health status. Those offsets are meaningful, but they are unlikely by themselves to neutralize an acquisition price approaching USD 40,000 per month. The decisive pharmacoeconomic question is therefore one of opportunity cost: what health gains must a healthcare system forgo elsewhere to finance broad access to daraxonrasib?

For regulators, payers, clinicians, and investors, the evidence supports two conclusions simultaneously. Daraxonrasib is a practice-changing therapy in previously treated RAS G12-mutated metastatic pancreatic cancer. The value of extending the same clinical and economic expectations to non-G12 disease or treatment-naive patients ineligible for multiagent therapy remains unproven.

1. The Approval and the Evidence Boundary

On August 26, 2026, the FDA approved RASONQUE for adults with metastatic pancreatic adenocarcinoma who either received at least one previous systemic therapy or are not candidates for multiagent systemic therapy. The label does not require identification of a specific RAS alteration and does not require a companion diagnostic. The recommended dose is 300 mg orally once daily until disease progression or unacceptable toxicity. (FDA approval announcement; FDA prescribing information)

This approval changes the treatment architecture of metastatic pancreatic cancer. Until now, systemic management was dominated by intravenous cytotoxic combinations, with targeted therapies confined to relatively uncommon molecular subgroups. Daraxonrasib introduces an oral therapy directed at the central oncogenic pathway present in most pancreatic ductal adenocarcinomas.

Yet the regulatory decision also creates an evidence boundary that must be stated precisely. The pivotal randomized evidence most directly supports patients with all of the following characteristics:

• Metastatic pancreatic adenocarcinoma.

• Previous systemic treatment for metastatic disease, or rapid metastatic recurrence after neoadjuvant or adjuvant therapy.

• ECOG performance status 0–1.

• A tumor harboring a RAS G12 mutation.

The approved population is broader in two directions: molecularly, because biomarker confirmation is unnecessary; and clinically, because the indication includes patients judged unsuitable for multiagent systemic treatment even if they have not received a previous metastatic regimen.

This is not a semantic distinction. It separates direct randomized evidence from regulatory extrapolation.

2. RASolute 302: Trial Architecture and Confirmatory Integrity

Study Design

RASolute 302, registered as NCT06625320, was a global, randomized, open-label Phase 3 trial enrolling 500 patients with metastatic pancreatic ductal adenocarcinoma. Patients were assigned to:

• Daraxonrasib 300 mg orally once daily: 248 patients.

• Investigator-selected standard-of-care chemotherapy: 252 patients.

The chemotherapy options were selected before randomization from four clinically relevant regimens. Among patients who received chemotherapy, use was distributed as follows:

• Gemcitabine plus nab-paclitaxel: 56.5%.

• Liposomal irinotecan plus 5-FU and leucovorin: 32.7%.

• Modified FOLFIRINOX: 5.6%.

• FOLFOX: 5.1%.

The comparator structure improved pragmatic relevance because it reflected treatment variation in practice. It also introduced heterogeneity in efficacy, toxicity, treatment duration, administration burden, and cost. The publication did not report chemotherapy regimen as a randomization stratification factor. Regimen-specific and trial-weighted sensitivity analyses are therefore important for both clinical and economic interpretation.

Endpoint Registration and Multiplicity

The original and current registered primary endpoints were the same:

• Progression-free survival in the RAS G12-mutated population.

• Overall survival in the RAS G12-mutated population.

There is no public evidence of endpoint switching. The statistical plan controlled multiplicity through a prespecified sequential framework, initially allocating 0.2% alpha to progression-free survival and 4.8% to overall survival. The confirmatory structure was therefore methodologically credible and aligned with the molecular population used to establish the primary claims. (ClinicalTrials.gov, NCT06625320; published Phase 3 report)

3. Clinical Benefit

Overall Survival

Median overall survival was 13.2 months with daraxonrasib and 6.7 months with chemotherapy, an absolute difference between medians of approximately 6.5 months. The hazard ratio for death was 0.40, corresponding to an estimated 60% reduction in the instantaneous risk of death during follow-up.

This effect is unusually large for previously treated metastatic pancreatic cancer. It is also the most important basis for describing the therapy as practice-changing. The hazard ratio—not the arithmetic subtraction of medians—provides the more complete summary of the relative survival effect across the observed study period.

Progression-Free Survival

Median progression-free survival was 7.2 months with daraxonrasib and 3.6 months with chemotherapy, producing an absolute median difference of approximately 3.6 months. The progression-free survival hazard ratio was approximately 0.49.

Objective response was also higher with daraxonrasib: approximately 30% versus 11% with chemotherapy.

Why the OS Gain Exceeded the PFS Gain

The absolute difference between median overall survival values was substantially larger than the difference between median progression-free survival values. That pattern is not inherently inconsistent, because medians summarize different points on different survival distributions. Nevertheless, it raises an attribution question that is clinically and economically important.

Potential explanations include:

• Better preservation of performance status at progression.

• Lower cumulative hematologic toxicity or neuropathy.

• Greater ability to receive subsequent therapy.

• Differences in post-progression treatment selection or initiation.

• A sustained biological effect after treatment discontinuation.

• Informative differences produced by post-randomization non-initiation of chemotherapy.

• Random variation associated with the timing and maturity of the interim analysis.

Post-progression therapies, treatment beyond progression, performance status at progression, and healthcare utilization must be disclosed in sufficient detail before the larger OS-than-PFS difference can be fully interpreted.

Data Maturity

The analysis occurred after a median follow-up of 8.5 months. It represented the prespecified first interim analysis of overall survival and the final analysis of progression-free survival.

The effect was large enough to cross the statistical boundary, but follow-up remained short relative to the 13.2-month median overall survival reported for daraxonrasib. The upper confidence limit for median overall survival had not yet been reached, and the long-term behavior of the survival curves remained immature.

Continued follow-up must determine whether:

• The survival separation persists beyond approximately one year.

• A durable survival tail emerges.

• The hazard ratio remains approximately proportional over time.

• The curves converge after treatment discontinuation or subsequent therapy.

These questions are not required to invalidate the current result. They determine the durability and mean survival gain needed for longer-term regulatory, clinical, and economic assessment.

4. Safety, Treatment Burden, and Quality of Life

Grade 3 or higher adverse events from any cause occurred in 61.8% of daraxonrasib-treated patients and 69.6% of chemotherapy-treated patients. Treatment-related grade 3 or higher events occurred in 43.6% and 57.5%, respectively. Serious treatment-related events occurred in 10.8% with daraxonrasib and 18.7% with chemotherapy.

Treatment-related discontinuation showed a particularly large difference:

• Daraxonrasib: 1.2%.

• Chemotherapy: 11.2%.

The toxicity profiles were qualitatively different. Chemotherapy generated greater hematologic toxicity, infection risk, peripheral neuropathy, dose modification, infusion burden, and treatment discontinuation. Daraxonrasib produced frequent dermatologic and gastrointestinal toxicity, particularly rash, diarrhea, mucositis, and stomatitis.

The trial also reported delayed deterioration in patient-reported outcomes:

• Median time to deterioration in pain: 9.2 versus 3.8 months.

• Median time to deterioration in global health status: 5.7 versus 2.6 months.

These findings suggest that additional survival was accompanied by preservation of symptoms and global quality of life rather than simply prolongation of a highly deteriorated health state. However, the open-label design, differences in treatment exposure, and differential treatment initiation must be considered when interpreting patient-reported outcomes.

5. From the Confirmatory Population to a Biomarker-Independent Label

Evidence in RAS G12-Mutated Disease

RAS G12 mutations were present in 459 of 500 randomized patients. This population accounted for 91.8% of the trial and formed the basis of the dual primary endpoint analysis. The trial therefore provides strong confirmatory evidence that daraxonrasib improves progression-free and overall survival in previously treated RAS G12-mutated metastatic pancreatic adenocarcinoma.

Evidence Outside RAS G12

Only 41 patients did not have a RAS G12 mutation. This group pooled several biologically distinct categories, including RAS G13, RAS Q61, and tumors without an identified RAS mutation.

The subgroup results were discordant:

• Overall survival: HR 0.37; 95% CI, 0.15–0.93, favoring daraxonrasib.

• Progression-free survival: HR 1.38; 95% CI, 0.60–3.17, numerically favoring chemotherapy.

Several technical limitations prevent this subgroup from independently validating mutation-agnostic efficacy.

First, the population was small and the confidence intervals were wide. Second, it combined different molecular mechanisms that should not automatically be assumed to have the same sensitivity to RAS(ON) inhibition. Third, the favorable overall-population result was mathematically dominated by the 91.8% of participants with RAS G12 disease. Fourth, the discordance between PFS and OS means that consistent tumor-control benefit was not demonstrated outside G12.

The OS estimate is clinically encouraging, but it may be affected by subsequent therapy, non-proportional hazards, baseline imbalance, and random instability in a small subgroup. A non-significant interaction test—if reported—would not prove equivalence of benefit across molecular groups; such tests are generally underpowered when one subgroup contains only 41 patients.

Separate estimates for G13, Q61, and RAS-unidentified tumors, together with biomarker-by-treatment interaction analyses and longer follow-up, are necessary to determine whether the broad label reflects true biological generalizability.

The Regulatory Question

The unresolved issue is whether a positive intention-to-treat analysis, driven numerically by RAS G12-mutated disease, justifies treatment without biomarker confirmation. The label may be clinically practical and avoids delaying therapy for testing. But absence of a mandatory companion diagnostic is not equivalent to evidence that every molecular subgroup derives the same benefit.

The scientifically defensible formulation is therefore:

Daraxonrasib has confirmed clinical value in previously treated RAS G12-mutated metastatic pancreatic cancer. Activity outside RAS G12 is plausible but incompletely established.

6. Extension to Patients Ineligible for Multiagent Therapy

The FDA indication includes patients who are not candidates for multiagent systemic therapy. This wording may allow treatment in newly diagnosed patients who are considered unable to tolerate combination chemotherapy.

RASolute 302, however, required ECOG performance status 0–1 and previous systemic treatment for metastatic disease, or metastatic recurrence within six months of neoadjuvant or adjuvant therapy. It did not directly evaluate a treatment-naive, clinically frail population with poor functional reserve, major comorbidity, or inability to tolerate multiagent treatment.

This creates several uncertainties:

• Frail patients may have different pharmacokinetics and toxicity tolerance.

• Their competing mortality and baseline life expectancy may reduce achievable absolute survival benefit.

• The relevant comparator may be single-agent therapy, attenuated chemotherapy, or best supportive care rather than the multiagent regimens used in the trial.

• Treatment discontinuation, adherence, and quality-of-life effects may differ from those observed in ECOG 0–1 participants.

• The opportunity cost may increase if treatment is applied to patients with a lower probability of receiving six months of meaningful benefit.

The label-defined population should therefore not be assigned the same expected clinical or economic value as the directly randomized population without additional prospective or high-quality real-world evidence.

7. Differential Treatment Initiation and the Open-Label Estimand

After randomization, 97.2% of patients assigned to daraxonrasib initiated therapy, compared with 84.9% assigned to chemotherapy. Twenty-nine control patients withdrew before receiving chemotherapy, compared with one patient assigned to daraxonrasib.

Randomization protects against baseline confounding at the moment of assignment. It does not prevent post-randomization behavior from altering the treatment contrast in an open-label trial. Here, knowledge of assignment appears to have influenced whether patients accepted the allocated therapy.

The primary intention-to-treat analysis remains formally valid for a treatment-policy estimand: it estimates the effect of assignment to a daraxonrasib strategy versus assignment to an investigator-selected chemotherapy strategy, including the consequences of acceptance or refusal after allocation.

It may not estimate the pure pharmacologic effect of receiving daraxonrasib versus receiving chemotherapy. If a substantial group assigned to chemotherapy received no active study treatment, the comparison partly incorporates the consequences of control-treatment refusal.

This does not automatically explain the large survival effect, but it requires sensitivity analysis. Appropriate analyses include:

• Intention-to-treat analysis.

• Per-protocol analysis with explicit acknowledgment that randomization is no longer preserved.

• As-treated analysis, similarly interpreted as nonrandomized.

• Inverse-probability weighting or other adjustment for treatment initiation.

• Hypothetical-estimand analysis assuming control patients had initiated their selected chemotherapy.

• Outcomes among patients who never began assigned treatment.

• Tipping-point or multiple-imputation analyses for informative nonadherence.

The objective is not to replace the intention-to-treat result. It is to determine how much of the estimated advantage is robust to the post-randomization initiation imbalance.

8. Pharmacology of Daraxonrasib

Pharmacologic Class

Daraxonrasib is an orally administered, noncovalent RAS(ON) multi-selective inhibitor. It is the first approved agent designed to inhibit the active, GTP-bound state of multiple mutant and wild-type RAS proteins through formation of a ternary molecular complex.

Unlike mutation-specific KRAS inhibitors, which recognize a particular amino-acid substitution, daraxonrasib is designed to inhibit multiple oncogenic RAS variants across KRAS, NRAS, and HRAS. Its pharmacologic activity is defined primarily by the activation state of RAS rather than by one mutation. “Multi-selective,” however, describes molecular design and preclinical activity; it does not demonstrate equal clinical efficacy across every RAS variant.

RAS Biology and the Active Target State

RAS proteins are small guanosine triphosphatases that alternate between an inactive GDP-bound state and an active GTP-bound state. Active RAS-GTP binds downstream effectors, including RAF, and initiates signaling through the RAF–MEK–ERK/MAPK pathway. This promotes proliferation, survival, metabolic adaptation, invasion, and immune evasion.

Oncogenic RAS mutations impair normal GTP hydrolysis or otherwise favor maintenance of the active state. Pancreatic ductal adenocarcinoma is especially dependent on this pathway, with RAS alterations present in the great majority of tumors and KRAS G12D, G12V, and G12R among the predominant variants.

Daraxonrasib differs from KRAS G12C(OFF) inhibitors such as sotorasib and adagrasib because it does not require mutant RAS to cycle into the inactive GDP-bound state. It directly engages active RAS-GTP, providing a pharmacologic strategy applicable to variants such as G12D, G12V, and G12R that are not adequately addressed by G12C-specific OFF-state inhibitors.

Tri-Complex Mechanism of Action

Daraxonrasib operates as a molecular glue. It first binds intracellular cyclophilin A, creating a binary daraxonrasib–cyclophilin A complex. That complex then recognizes a composite surface formed by the switch I and switch II regions of active RAS-GTP. The final ternary complex contains:

1. Cyclophilin A.

2. Daraxonrasib.

3. Active RAS-GTP.

The drug therefore does not merely occupy a conventional pocket on RAS. It remodels the surface of cyclophilin A to create a new protein–protein interface capable of engaging active RAS.

Formation of the complex produces two principal effects:

• Steric blockade of RAS-GTP interaction with downstream effectors such as RAF.

• Promotion of GTP hydrolysis, shifting RAS toward the inactive GDP-bound state.

The resulting suppression of RAS–MAPK signaling inhibits proliferation and can induce tumor-cell death. Preclinical RAS-dependent pancreatic cancer models demonstrated tumor-growth inhibition and regression, with evidence of associated antitumor immune activity. (Cregg et al., Journal of Medicinal Chemistry)

Molecular Selectivity and the Therapeutic Margin

Daraxonrasib is a macrocyclic molecule developed through structure-guided optimization of interactions with residues conserved across RAS isoforms. It can inhibit active forms of KRAS, NRAS, and HRAS, including G12, G13, and Q61 substitutions, as well as activated wild-type RAS.

Inhibition of wild-type RAS may reduce compensatory signaling through nonmutated RAS proteins, a mechanism capable of limiting mutation-selective agents. The same property may narrow the therapeutic margin because normal tissues depend on physiologic RAS signaling. Frequent dermatologic and gastrointestinal toxicities are consistent with pathway inhibition in proliferative normal tissues, although the contribution of wild-type RAS inhibition to individual adverse reactions has not been definitively separated from other pharmacologic effects.

Pharmacodynamics and Dose Selection

Preclinical models showed antiproliferative activity across RAS-dependent cell lines and tumor regression in pancreatic, lung, and colorectal models. PK/PD modeling suggested that sustained pathway suppression would be necessary for meaningful tumor control. Exposures corresponding to approximately 100 mg daily were predicted to control growth, whereas those corresponding to 300 mg daily were expected to produce deeper suppression and objective responses.

The translational model predicted at least 90% suppression of RAS-pathway signaling across the clinically active 160–300 mg daily exposure range and supported selection of 300 mg once daily for the pivotal program. Nevertheless, the FDA label states that the clinical exposure–efficacy relationship and time course of pharmacodynamic response remain incompletely characterized. (Jiang et al., Cancer Discovery)

Exposure–toxicity relationships are clearer. Across doses of 10–400 mg once daily, increasing exposure was associated with greater incidence of dose interruption, reduction, or discontinuation; grade 3 or higher adverse reactions; dermatologic toxicity; stomatitis; nausea; vomiting; and diarrhea.

At the approved dose, daraxonrasib did not produce a mean QTc increase greater than 20 milliseconds.

Formulation and Administration

Daraxonrasib has the molecular formula C44H58N8O5S and a molecular weight of 811.06 g/mol. It is a large macrocyclic compound operating beyond conventional Rule-of-Five chemical space.

Its aqueous solubility is strongly pH dependent:

• Greater than 10 mg/mL at pH 1.2.

• Approximately 0.009 mg/mL at pH 6.8.

The product is formulated as a spray-dried dispersion incorporated into film-coated tablets. Despite the pH-dependent solubility, esomeprazole did not produce a clinically significant pharmacokinetic change. Daraxonrasib may be administered with or without food.

The approved dose is 300 mg orally once daily. Tablets must be swallowed whole and should not be crushed, chewed, or divided. Available strengths are 100 mg and 150 mg.

For toxicity, recommended sequential dose reductions are:

• First reduction: 200 mg once daily.

• Second reduction: 150 mg once daily.

Permanent discontinuation is recommended when 150 mg once daily cannot be tolerated. Interaction-specific management may require temporary dosing at 100 mg or an increase to 400 mg when unavoidable enzyme induction substantially reduces exposure.

Pharmacokinetics

After 300 mg once daily:

• Geometric mean maximum concentration: approximately 365 ng/mL.

• Geometric mean AUC: approximately 3,760 ng·h/mL.

• Median time to maximum concentration: 2.2 hours.

• Observed Tmax range: 0.67–8.0 hours.

AUC increases approximately proportionally between 80 and 300 mg, while Cmax increases less than proportionally. Repeated daily administration produces minimal or no accumulation in AUC. A high-fat, high-calorie meal does not cause a clinically meaningful exposure change.

The apparent terminal volume of distribution is approximately 1,060 L, indicating extensive distribution outside the vascular compartment. Plasma-protein binding is approximately 98% and is not concentration dependent. The blood-to-plasma concentration ratio ranges from 1.7 to 2.6, suggesting preferential association with cellular blood components.

Daraxonrasib is metabolized primarily by CYP3A. Mean terminal elimination half-life is approximately 9.2 hours, and apparent oral clearance is approximately 80.4 L/hour.

After a radiolabeled oral dose:

• Approximately 93% of radioactivity was recovered in feces.

• Approximately 51% of the administered dose was recovered unchanged in feces.

• Approximately 1% was recovered in urine.

• Approximately 1% was recovered unchanged in urine.

Renal elimination is therefore minimal. Fecal recovery represents a combination of unabsorbed drug and hepatobiliary elimination.

Drug–Drug Interactions

Daraxonrasib is a substrate of CYP3A and P-glycoprotein and also inhibits P-glycoprotein. Strong combined CYP3A and P-gp inhibition can markedly increase exposure. Itraconazole increased AUC approximately 5.1-fold and should be avoided.

Other observed or predicted changes include:

• Voriconazole: approximately twofold AUC increase.

• Verapamil: approximately 2.6-fold increase.

• Fluconazole: approximately 1.5-fold increase.

• Quinidine: approximately 1.8-fold increase.

• Phenytoin: reduction of AUC to approximately 50%.

• Rifampin: predicted reduction to approximately 30%.

• Moderate CYP3A inducers: predicted reduction to approximately 50–84%.

Strong CYP3A inhibitors without P-gp inhibition require reduction to 150 mg daily. Moderate CYP3A inhibitors require reduction to 100 or 200 mg depending on concomitant P-gp inhibition. P-gp inhibitors require reduction to 150 mg. Strong CYP3A inducers should generally be avoided; if unavoidable, the label permits 400 mg once daily. Moderate CYP3A inducers also require 400 mg daily.

Because daraxonrasib inhibits P-gp, sensitive P-gp substrates should be administered at least four hours apart. Modeling predicted a substantial increase in free dabigatran exposure with simultaneous administration.

Systemic cyclosporine and its derivatives should be avoided. Both cyclosporine and daraxonrasib interact with cyclophilin A, potentially altering exposure, activity, and safety.

Special Populations

No clinically significant pharmacokinetic differences were identified by age from 19 to 87 years, sex, race, body weight from 37 to 171 kg, ECOG performance status 0 or 1, tumor burden, mild or moderate renal impairment, or mild or moderate hepatic impairment.

Pharmacokinetics remain unknown in severe renal impairment, defined as creatinine clearance below 30 mL/min, and in severe hepatic impairment. No overall efficacy or safety differences were observed between adults aged 65 years or older and younger adults. Pediatric safety and efficacy have not been established.

These findings should not be used to assume comparable tolerability in frail, treatment-naive patients who were not represented in the pivotal trial.

Clinically Relevant Toxicity

The toxicity profile is dominated by dermatologic and gastrointestinal events:

• Dermatologic toxicity occurred in approximately 86% of exposed pancreatic cancer patients, with a median onset of 13 days.

• Diarrhea occurred in approximately 63%, with a median onset of three days.

• Stomatitis occurred in approximately 57%, with a median onset of 22 days.

Prophylactic topical corticosteroids, emollients, sun protection, and, where appropriate, oral tetracycline antibiotics are recommended from treatment initiation. Stomatitis may require steroid-containing mouthwash and other topical treatment.

Less frequent but potentially fatal or clinically serious toxicities include:

• Gastrointestinal perforation: approximately 0.9%.

• Interstitial lung disease or pneumonitis: approximately 2.4%.

• Renal-limited thrombotic microangiopathy: 0.4% in RASolute 302.

• Embryo-fetal toxicity.

The high frequency of interruption and reduction—69% and 37%, respectively, in the label safety population—means daraxonrasib should not be modeled or managed as a low-monitoring oral therapy.

Serious adverse reactions from any cause occurred in approximately 30% of exposed patients in the label safety population. This reinforces the need for active toxicity prevention, rapid dose modification, and access to clinical monitoring despite the convenience of oral administration.

Reproductive and Nonclinical Toxicology

Daraxonrasib caused fetal mortality, impaired growth, and structural malformations in mice at exposures at least 2.5 times human exposure at the recommended dose. Effective contraception is required during treatment and for one week after the final dose. Breastfeeding is not recommended during treatment or for one week afterward.

The drug was not mutagenic, clastogenic, or genotoxic in the standard assays reported in the label. Formal carcinogenicity and fertility studies have not been conducted.

In a four-week mouse toxicity study, increased bone remodeling and structural bone changes occurred at exposures equal to or greater than human exposure at the approved dose. The relevance of this finding to longer-term human treatment remains uncertain.

Acquired Resistance

Daraxonrasib suppresses RAS signaling but does not eliminate tumor evolution. Paired circulating-tumor DNA from 44 patients with pancreatic cancer who initially benefited and later progressed identified treatment-emergent RAS-pathway alterations in 59%.

Reported mechanisms included:

• Mutant KRAS amplification: 36%.

• MAPK-pathway alterations: 25%.

• Receptor-tyrosine-kinase alterations: 9%.

• PI3K-pathway alterations: 9%.

• MYC amplification and other mechanisms capable of restoring oncogenic signaling.

These alterations converge on amplification or reactivation of pathway flux, enabling tumors to overcome the degree of suppression achievable with monotherapy.

Secondary KRAS mutations capable of disrupting tri-complex formation have been observed in non-pancreatic tumors and preclinical models, particularly at residues located at the daraxonrasib–RAS–cyclophilin interface. They were not detected in the analyzed pancreatic cohort. (Resistance analysis, Nature Medicine)

Pharmacologic Interpretation

Daraxonrasib is a mechanistic advance because it converts cyclophilin A into a pharmacologic recognition surface for active RAS. This overcomes both the absence of a conventional binding pocket and the dependence of first-generation mutation-specific inhibitors on the inactive RAS state.

Its principal strengths are direct engagement of RAS-GTP, activity across several oncogenic variants, suppression of mutant and wild-type RAS signaling, oral administration, limited renal elimination, and absence of a clinically meaningful food or proton-pump-inhibitor effect.

Its limitations include an incompletely characterized exposure–efficacy relationship, high interpatient pharmacokinetic variability, substantial CYP3A and P-gp interaction potential, frequent exposure-dependent toxicity, acquired resistance through pathway reactivation, and absence of equivalent clinical validation across all molecular subtypes included in its pharmacologic range.

The drug should therefore be described as a broad RAS-pathway inhibitor with its strongest clinical validation in previously treated RAS G12-mutated pancreatic adenocarcinoma—not as a therapy proven equally effective across every RAS-dependent tumor.

9. Pharmacoeconomics and Opportunity Cost

The Correct Economic Question

Daraxonrasib combines a major clinical benefit with a very high acquisition price. The relevant economic question is not merely how much the drug costs per month or whether it prolongs survival. It is:

What health benefits must the healthcare system forgo elsewhere to finance daraxonrasib, and does the additional health generated exceed the health displaced?

This separates individual value from system affordability. A therapy may be highly valuable to a treated patient while producing limited or negative population net health benefit if its budget impact displaces more cost-effective care elsewhere.

Acquisition Cost

The reported wholesale acquisition cost is USD 39,800 per 30-day supply, corresponding to an annualized list price of approximately USD 477,600. WAC is not the net price paid by insurers because it excludes rebates, discounts, and other concessions, but it establishes the scale of expenditure at launch. (Revolution Medicines SEC filing)

Median daraxonrasib treatment duration in RASolute 302 was 6.2 months. Applying WAC produces an estimated gross acquisition cost of:

USD 39,800 × 6.2 months = approximately USD 246,760 per treated patient.

Using the 7.2-month median PFS as a less direct duration proxy would increase gross acquisition cost to approximately USD 286,560. Observed treatment duration is the more defensible starting point, but a formal model requires patient-level time on treatment, dose intensity, discontinuation, wastage, and net price.

Dose reductions may not yield proportional savings because tablet pricing, dispensing cycles, and unused medication weaken the relationship between prescribed dose and expenditure.

Preliminary Cost-to-Outcome Screening

Daraxonrasib increased median PFS by approximately 3.6 months and median OS by approximately 6.5 months. Dividing the estimated USD 246,760 gross acquisition cost by those differences yields:

• Approximately USD 68,500 per additional median PFS month.

• Approximately USD 455,600 per median life-year proxy.

If the additional 6.5 median survival months were assigned an illustrative utility of 0.80, they would correspond to approximately 0.433 QALY, generating a gross drug-cost proxy of approximately USD 569,000 per QALY.

These calculations are not formal ICERs. Differences between medians are not differences between mean life-years or QALYs. A valid cost-effectiveness model must integrate the full PFS and OS curves, apply health-state utilities, include all relevant costs, and extrapolate beyond the observed trial period.

The short follow-up creates two competing possibilities. A durable survival tail could increase mean life-years and improve cost-effectiveness. Convergence of the curves after current follow-up could reduce the mean gain and worsen it.

Illustrative Opportunity-Cost Thresholds

Using the 6.5-month median OS difference as an unadjusted life-year proxy, the maximum incremental expenditure compatible with thresholds of USD 100,000, USD 150,000, and USD 200,000 per life-year would be approximately USD 54,200, USD 81,300, and USD 108,300, respectively.

If the same survival difference were assigned the illustrative utility weight of 0.80 used above, the corresponding value ceilings would instead be:

• Approximately USD 43,300 at USD 100,000 per QALY.

• Approximately USD 65,000 at USD 150,000 per QALY.

• Approximately USD 86,700 at USD 200,000 per QALY.

Against gross acquisition cost of approximately USD 246,760, conventional thresholds would require substantial rebates, downstream savings, a larger mean survival gain than the median proxy, or some combination of these factors.

At USD 150,000 per QALY and the illustrative utility of 0.80, the gap between gross acquisition cost and the screening-level value ceiling is approximately USD 181,800 per patient. This does not imply absence of clinical value. It indicates that the launch price captures a large share of expected benefit and may leave limited net health gain after displaced care is considered. Because medians are not means and the utility is hypothetical, none of these ceilings should be used as a reimbursement recommendation without a complete model.

Quality-Adjusted Survival

Daraxonrasib delayed deterioration in pain and global health status and caused fewer treatment-related grade 3 or higher events and discontinuations than chemotherapy. These findings support the possibility that survival gains include higher-quality time.

The trial used EORTC QLQ-C30 and QLQ-PAN26 instruments rather than a direct preference-based measure such as EQ-5D. Time-to-deterioration cannot be converted directly into QALYs.

A formal model requires one of the following:

• Patient-level EQ-5D data.

• A validated mapping algorithm from EORTC QLQ-C30 to EQ-5D.

• Published utilities for progression-free and progressed metastatic pancreatic cancer, adjusted for treatment-specific adverse events.

Open-label reporting and different treatment exposure must also be incorporated into uncertainty analyses for quality-of-life estimates.

Treatment-Related Cost Offsets

Daraxonrasib may avoid or reduce:

• Chemotherapy acquisition.

• Infusion-center and pharmacy-preparation costs.

• Central venous access and device management.

• Laboratory and administration visits.

• Antiemetic and growth-factor use.

• Treatment of neutropenia, anemia, thrombocytopenia, and infection.

• Hospitalization related to hematologic toxicity.

• Management of peripheral neuropathy.

• Transportation, caregiver time, and productivity loss associated with infusions.

The trial's lower rates of severe treatment-related events, serious treatment-related events, and discontinuation support meaningful administration and toxicity offsets. They are unlikely, however, to offset a USD 39,800 monthly acquisition cost on their own.

Daraxonrasib also produces management costs, including prophylactic skin treatment, possible tetracycline antibiotics, stomatitis and diarrhea management, dose modification, laboratory monitoring, and evaluation of pneumonitis, gastrointestinal perforation, thrombotic microangiopathy, electrolyte abnormalities, and hepatic or hematologic changes.

Comparator Heterogeneity

The control arm cannot be represented as a single chemotherapy cost. The four regimens differ in price, schedule, toxicity, and median duration, which ranged from approximately 1.5 to 3.2 months.

The base case should preserve the trial-weighted comparator mix. Scenario analyses should separately compare daraxonrasib with:

• Gemcitabine plus nab-paclitaxel.

• Liposomal irinotecan plus 5-FU and leucovorin.

• Modified FOLFIRINOX.

• FOLFOX.

• Single-agent or best supportive care for patients unable to receive active multiagent therapy.

Collapsing these regimens into one average without maintaining regimen-specific duration, administration, and toxicity would obscure the incremental cost and could materially bias the result.

Post-Progression Economics

The difference between PFS and OS makes post-progression economics central to the model. Required data include:

• Whether daraxonrasib continued beyond radiographic progression.

• Subsequent treatment by randomized arm.

• Performance status at progression.

• Time from progression to next therapy.

• Hospitalization and supportive-care use after progression.

• End-of-life care.

If acquisition cost stops at progression but a biological or functional survival benefit continues, cost-effectiveness improves. If the OS difference depends on expensive subsequent therapies or unequal treatment access, the benefit directly attributable to daraxonrasib becomes smaller. Without detailed post-progression data, the economic mechanism remains unresolved.

Biomarker Strategy as an Economic Tool

Avoiding mandatory biomarker testing reduces diagnostic cost and may accelerate access. Yet tumor profiling is inexpensive relative to several months of treatment.

Testing may still improve allocative efficiency by:

• Identifying the population with the strongest evidence of benefit.

• Detecting alternative actionable drivers in RAS-unidentified tumors.

• Avoiding high-cost treatment when expected effectiveness is uncertain.

• Supporting outcomes-based contracting and real-world evidence generation.

A biomarker-independent label may maximize commercial access while reducing average economic efficiency if substantial treatment is delivered to molecular groups with uncertain benefit.

Economic Segmentation of the Label

A single cost-effectiveness result should not be applied to the entire FDA indication.

Previously Treated RAS G12-Mutated Disease

This is the best-supported group and the one most likely to generate acceptable value because both PFS and OS effects are confirmed and large. The price remains challenging, but clinical uncertainty is lowest.

Previously Treated Non-G12 or RAS-Unidentified Disease

The small sample and discordant PFS and OS estimates create major uncertainty around incremental life-years and QALYs. Expected value may be lower, and probabilistic sensitivity analysis should reflect broad effectiveness distributions rather than applying the G12 treatment effect.

Patients Not Eligible for Multiagent Therapy

Treatment-naive frail patients were not directly studied. Their baseline survival, tolerability, treatment duration, comparator, utility, and resource use may differ substantially. A separate model populated with prospective or real-world evidence is necessary.

Economic Consequences of Differential Initiation

Treatment non-initiation complicates both costs and outcomes. An intention-to-treat cost analysis may assign low chemotherapy cost to patients who never received chemotherapy, while retaining their outcomes in the control arm. An as-treated analysis may introduce confounding by destroying randomization.

A complete evaluation should report:

• Intention-to-treat costs and outcomes.

• Per-protocol and as-treated analyses with explicit limitations.

• Treatment-policy and hypothetical estimands.

• Imputation scenarios in which control withdrawals initiate chemotherapy.

• Costs and survival among non-initiators.

The objective is to assess the sensitivity of both incremental cost and incremental effectiveness to post-randomization behavior.

Budget Impact

At the estimated gross acquisition cost of USD 246,760 per patient:

• 100 patients generate approximately USD 24.7 million in drug expenditure.

• 1,000 patients generate approximately USD 246.8 million.

• 5,000 patients generate approximately USD 1.23 billion.

• 10,000 patients generate approximately USD 2.47 billion.

These estimates exclude rebates, offsets, and variation in treatment duration, but they demonstrate the scale of possible displacement. The broad biomarker-independent label and potential treatment of patients before multiagent therapy materially increase budget exposure.

Displaced activity could include other oncology therapies, diagnostic and screening programs, supportive and palliative services, clinical staffing, or interventions in other diseases that produce more health per dollar.

Patient and Payer Consequences

As an oral therapy, daraxonrasib may shift expenditure from the medical benefit used for infused chemotherapy to the pharmacy benefit. Consequences may include:

• Specialty-pharmacy expenditure and prior authorization.

• Treatment delay during coverage review.

• High patient cost sharing and financial toxicity.

• Different exposure under commercial insurance and Medicare.

• Administrative burden for oncology centers.

• Dependence on manufacturer assistance.

• Unequal access among insured, underinsured, and uninsured patients.

Assistance programs may reduce individual out-of-pocket spending but do not eliminate the underlying opportunity cost borne by the healthcare system.

Required Economic Model

A defensible evaluation should use a partitioned-survival or state-transition framework with progression-free disease, progressed disease, and death as the principal health states.

It should incorporate:

• Reconstructed or patient-level PFS and OS curves.

• Alternative parametric extrapolations.

• Time-varying hazards where appropriate.

• Regimen-specific comparator costs.

• Time on treatment and relative dose intensity.

• Adverse-event, hospitalization, administration, and monitoring costs.

• Subsequent therapy and end-of-life care.

• Health-state and adverse-event utilities.

• Biomarker-testing costs.

• Patient and caregiver time in a societal perspective.

• Net-price and rebate scenarios.

• Molecular-subtype-specific effectiveness.

• A separate analysis for patients ineligible for multiagent therapy.

Required outputs include incremental cost per life-year and per QALY, incremental net monetary benefit, population net health benefit, one-, three-, and five-year budget impact, probabilistic sensitivity analysis, and value-of-information analysis.

Preliminary Economic Conclusion

Daraxonrasib delivers one of the largest reported survival effects in previously treated metastatic pancreatic cancer. That creates substantial individual and social value. At the same time, a monthly WAC of USD 39,800 produces gross median acquisition cost approaching USD 250,000 per patient.

Conventional cost-effectiveness thresholds will be difficult to meet without significant net-price reductions, durable long-term survival, substantial quality-of-life gains, large downstream offsets, or restriction to populations with the strongest expected benefit.

The central economic risk is not use in the well-supported RAS G12-mutated second-line population. It is expansion of a high-cost therapy into biomarker-negative or clinically frail populations for which the incremental benefit has not been established.

10. Revolution Medicines: Corporate Position

Company Evolution

Revolution Medicines, Inc. is a global, commercial-stage oncology company headquartered in Redwood City, California, incorporated in Delaware, and traded on Nasdaq under RVMD.

The company was founded in October 2014 and launched publicly by Third Rock Ventures in February 2015 with a USD 45 million Series A financing. Its initial focus was the redesign of natural products into therapeutic compounds. (Company launch)

Its present identity emerged through several transactions:

• The 2018 acquisition of Warp Drive Bio supplied the scientific foundation for the tri-complex platform and strengthened the focus on RAS-driven cancers.

• The February 2020 IPO established RVMD as a Nasdaq-listed company.

• The November 2023 all-stock acquisition of EQRx added approximately USD 1.1 billion in net cash and investments while substantially increasing the outstanding share count.

• FDA approval of RASONQUE in August 2026 converted the organization from a development-stage biotechnology company into a commercial-stage oncology company.

Platform and Pipeline

Revolution Medicines has built an integrated portfolio around two categories of oral RAS(ON) inhibitors:

• Multi-selective compounds designed to inhibit several oncogenic variants.

• Mutant-selective compounds directed at defined variants such as G12C, G12D, or G12V.

The clinical and research portfolio includes:

• Daraxonrasib (RMC-6236): approved in metastatic pancreatic adenocarcinoma and under study in earlier pancreatic cancer settings and RAS-mutated non-small cell lung cancer.

• Zoldonrasib (RMC-9805): a G12D-selective inhibitor under evaluation as monotherapy and with chemotherapy or daraxonrasib.

• Elironrasib (RMC-6291): a G12C-selective inhibitor focused substantially on non-small cell lung cancer.

• RMC-5127: a G12V-selective inhibitor in early clinical development.

• RMC-0708 and RMC-8839: earlier programs targeting Q61H and G13C.

• RM-055: a representative of a new RAS(ON) inhibitor class intended to address resistance.

The shared platform creates development efficiency, combination opportunities, and the possibility of franchise expansion across pancreatic, lung, and colorectal cancers. It also produces correlated scientific risk: a platform-level safety issue, resistance mechanism, manufacturing problem, or intellectual-property challenge could affect several assets at once.

Commercialization and Geographic Expansion

Before approval, an FDA-cleared expanded-access program distributed daraxonrasib on behalf of more than 2,000 patients through participating centers across almost all U.S. states and Puerto Rico. This likely accelerated physician familiarity, operational readiness, and awareness before launch, but expanded access does not ensure payer coverage or commercial conversion. (Second-quarter 2026 corporate update)

The company is also building international reach through partnerships. Its August 2026 agreement with BeOne Medicines granted BeOne exclusive development or commercialization rights to four RAS(ON) inhibitors in selected Asian markets. Revolution Medicines retained rights outside the licensed territories, including Japan and South Korea, and became eligible for milestones and tiered royalties. The transaction provides regional development and commercial infrastructure without requiring fully independent expansion into every market. (BeOne collaboration)

Clinical collaborations with Summit Therapeutics, Tango Therapeutics, Bristol Myers Squibb, and other organizations support combination strategies involving PD-1/VEGF bispecific antibodies, PRMT5 inhibitors, and other complementary agents.

Leadership and Governance

The company is led by founding President, Chief Executive Officer, and Board Chair Mark A. Goldsmith, M.D., Ph.D. Principal executives include Chief Financial Officer Jack Anders, Chief Operating Officer Margaret Horn, Chief Development Officer Alan Sandler, Chief Global Commercialization Officer Anthony Mancini, and General Counsel and Corporate Secretary Jeffrey Cislini. (2026 Proxy Statement)

The leadership group combines drug discovery, oncology development, finance, and commercialization experience. The combination of CEO and board-chair roles nevertheless concentrates executive and governance authority in one individual.

Financial Capacity and Capital Structure

At June 30, 2026, Revolution Medicines reported approximately USD 3.9 billion in cash, cash equivalents, and marketable securities. The balance reflected:

• USD 1.725 billion from an April 2026 common-stock offering.

• USD 500 million in 0.50% convertible senior notes due in 2033.

• A USD 250 million Royalty Pharma payment received in May 2026.

The company reported up to an additional USD 1.5 billion in committed capital under Royalty Pharma arrangements, subject to milestones and contractual conditions.

Financial capacity must be interpreted alongside expenditure. Net loss reached approximately USD 1.10 billion during the first six months of 2026, and full-year GAAP operating-expense guidance was USD 2.1–2.2 billion, including substantial noncash stock-based compensation. (Second-quarter 2026 financial results)

Royalty financing reduces immediate capital pressure but transfers part of future product economics to Royalty Pharma and creates contractual obligations. Equity issuance diluted existing ownership, while convertible notes introduce potential future dilution and debt-service considerations.

Corporate Strengths and Dependencies

The company's strengths include first-mover regulatory validation, a differentiated platform, a broad and integrated pipeline, substantial capital, oral products, and potential application across several high-incidence tumors.

Its principal dependency is concentration. RASONQUE is the only approved product, and most pipeline value rests on the same RAS(ON) strategy. Other material risks include:

• First-product commercial execution and payer access.

• Dependence on third-party manufacturing.

• High operating expenditure and cash consumption.

• Royalty obligations and continuing dilution risk.

• Immature evidence for several combinations.

• Dependence on successful expansion into earlier treatment lines and additional tumors.

• Uncertain value outside RAS G12-mutated disease.

• Acquired resistance across the RAS pathway.

Long-term corporate value will depend on whether the platform generates multiple independently successful products rather than a single approved medicine.

11. Competitive Landscape

Current Market Competition

RASONQUE has no exact commercial equivalent: no other approved oral broad RAS inhibitor has the same metastatic pancreatic cancer positioning. Its immediate competition therefore comes from existing treatment strategies rather than a like-for-like targeted product.

Ipsen's ONIVYDE (liposomal irinotecan) competes directly in some previously treated patients when combined with 5-FU and leucovorin and indirectly in first-line disease through NALIRIFOX. (FDA ONIVYDE approval)

Generic or multi-manufacturer chemotherapy backbones—including gemcitabine plus nab-paclitaxel, modified FOLFIRINOX, FOLFOX, and other fluorouracil-based combinations—retain established reimbursement, physician familiarity, and substantially lower acquisition cost. Their disadvantages are infusion burden, hematologic toxicity, neuropathy, and treatment discontinuation.

The commercial contest will therefore involve not only survival but also convenience, toxicity, quality of life, reimbursement, and incremental cost.

Biomarker-Defined Alternatives

Several targeted therapies compete only within small molecular subgroups:

• Merus's BIZENGRI (zenocutuzumab) is approved for previously treated pancreatic adenocarcinoma with an NRG1 fusion. It requires molecular identification and intravenous administration. (FDA)

• AstraZeneca and Merck's LYNPARZA (olaparib) is used as first-line maintenance in germline BRCA-mutated metastatic disease that has not progressed after platinum chemotherapy. It occupies a different treatment position and overlaps only partially.

• Merck's KEYTRUDA (pembrolizumab) may be used in MSI-H, mismatch-repair-deficient, or tumor-mutational-burden-high solid tumors after previous therapy where no satisfactory alternative exists. These biomarkers occur in a small minority of pancreatic cancers.

These therapies do not challenge the breadth of RASONQUE's label, but they reinforce the value of molecular testing because a RAS-unidentified tumor may contain a different actionable driver.

Erasca: The Closest Broad RAS Competitor

Erasca's investigational ERAS-0015 is an oral pan-RAS molecular glue being developed in KRAS-mutated solid tumors. Preliminary Phase 1 results in previously treated KRAS G12X pancreatic cancer and planned potentially registration-enabling studies make it the closest conceptual competitor to daraxonrasib's broad, oral, later-line positioning. (Erasca)

Its current evidence is based on small, nonrandomized populations and cannot be equated with randomized Phase 3 survival evidence. If later trials confirm comparable efficacy with lower toxicity, simpler interactions, or more favorable pricing, ERAS-0015 could materially reduce daraxonrasib's first-mover advantage.

Astellas: The Strongest G12D First-Line Challenger

Astellas is developing setidegrasib (ASP3082), a selective KRAS G12D protein degrader. In April 2026, the company initiated a randomized Phase 3 trial combining setidegrasib with mFOLFIRINOX or NALIRIFOX in first-line KRAS G12D-mutated metastatic pancreatic cancer. (Astellas)

Setidegrasib does not directly challenge the current later-line RASONQUE indication. It is a major threat to Revolution Medicines' earlier-line strategy and particularly to zoldonrasib. A positive Phase 3 result could establish mutation-specific degradation in first-line G12D disease before Revolution Medicines consolidates its own franchise.

Immuneering: A Biomarker-Independent First-Line Threat

Immuneering's atebimetinib is an oral MEK-pathway inhibitor being combined with modified gemcitabine and nab-paclitaxel in the global Phase 3 MAPKeeper 301 trial for first-line metastatic pancreatic cancer. The primary endpoint is overall survival. (Immuneering)

Atebimetinib is not a direct RAS inhibitor, but its biomarker-independent development strategy could compete with daraxonrasib's move into first-line disease. Its relevance is therefore indication-level rather than mechanism-level.

Verastem and GenFleet: Dual-State G12D Inhibition

Verastem is developing VS-7375, originally discovered by GenFleet, as an oral inhibitor targeting both active and inactive KRAS G12D. A registration-directed Phase 2 program is evaluating the compound in previously treated G12D-mutated metastatic pancreatic cancer. (Verastem)

VS-7375 directly challenges zoldonrasib and could compete with daraxonrasib within the large G12D subgroup. The dual ON/OFF mechanism is intended to provide more complete pathway suppression, but comparative clinical superiority has not been established.

Eli Lilly and Bristol Myers Squibb

Eli Lilly's LY4066434 is an oral pan-KRAS inhibitor covering several common mutations, including G12C, G12D, G12V, G12A, G12S, and G13D. It is being evaluated in pancreatic, colorectal, and lung cancers as monotherapy and in combinations. The program remains earlier in development but represents a major platform threat because Lilly has extensive development, manufacturing, payer, and commercial capabilities. (ClinicalTrials.gov, NCT06607185)

Bristol Myers Squibb acquired a major RAS portfolio through Mirati Therapeutics. Relevant assets include the approved G12C inhibitor KRAZATI (adagrasib) and the investigational G12D inhibitor MRTX1133. Bristol Myers Squibb is simultaneously a Revolution Medicines collaborator in selected combination work and a potential competitor across RAS-driven tumors. (Bristol Myers Squibb)

Competition Beyond Pancreatic Cancer

Expansion into non-small cell lung cancer brings Revolution Medicines into a more mature KRAS market. Elironrasib faces the approved G12C products LUMAKRAS (sotorasib) from Amgen and KRAZATI (adagrasib) from Bristol Myers Squibb, together with investigational agents including Roche/Genentech's divarasib, Eli Lilly's olomorasib and LY4066434, and Merck's MK-1084. Daraxonrasib's non-G12C strategy also faces ERAS-0015, setidegrasib, other mutation-selective programs, and pathway-level combinations.

Approved G12C agents do not directly compete with daraxonrasib in non-G12C disease, but they establish expectations for response, durability, intracranial activity, tolerability, sequencing, price, and combination compatibility.

Competitive Ranking

The principal threats can be ordered by strategic proximity:

1. Ipsen and established chemotherapy: immediate commercial and payer alternatives in the current indication.

2. Erasca: closest future broad, oral, later-line RAS competitor.

3. Astellas: strongest late-stage challenge to the first-line G12D franchise.

4. Immuneering: biomarker-independent competition for first-line expansion.

5. Verastem/GenFleet: mutation-specific competition in previously treated G12D disease.

6. Eli Lilly and Bristol Myers Squibb: large-scale platform competitors with superior global resources.

Revolution Medicines currently holds the advantages of approval, randomized survival evidence, oral administration, and a broad label. That advantage could narrow if another company demonstrates comparable survival with a safer or more selective mechanism, simpler pharmacology, lower net price, or compelling first-line data.

12. Implications for Decision-Makers, CEOs, and Investors

The Strategic Inflection Point

The approval of RASONQUE removes the principal regulatory risk surrounding daraxonrasib but replaces it with three execution risks:

1. Converting a broad FDA label into reimbursed commercial demand.

2. Generating evidence for populations extending beyond the pivotal trial.

3. Demonstrating that the RAS(ON) platform can produce multiple successful products rather than a single commercial asset.

The Phase 3 survival benefit provides Revolution Medicines with a strong clinical foundation and a first-mover advantage. However, regulatory approval, payer acceptance, clinical adoption, and economic value are separate thresholds. The company has crossed the first; it must still prove the remaining three.

For Healthcare and Regulatory Decision-Makers

The evidence strongly supports daraxonrasib in previously treated, RAS G12-mutated metastatic pancreatic adenocarcinoma. The decision becomes more complex outside that population.

RAS G12 mutations accounted for 91.8% of randomized patients and formed the trial’s confirmatory population. Only 41 patients were outside RAS G12, with discordant results: overall survival favored daraxonrasib, while progression-free survival numerically favored chemotherapy. The FDA label nevertheless does not require biomarker testing.

Decision-makers should therefore distinguish between:

• Regulatory eligibility: the complete population permitted by the FDA label.

• Evidence-supported eligibility: the population directly validated by the pivotal trial.

• Economically efficient eligibility: patients in whom expected health gains justify the opportunity cost.

These groups may not be identical.

The inclusion of patients who are not candidates for multiagent systemic therapy creates an additional evidence gap. RASolute 302 enrolled previously treated patients with ECOG performance status 0–1. Newly diagnosed, clinically frail patients unable to tolerate combination therapy were not directly studied.

Postmarketing evidence should prioritize:

• Molecularly resolved outcomes for RAS G12, G13, Q61 and RAS-unidentified disease.

• Effectiveness and tolerability in treatment-naive, multiagent-ineligible patients.

• Outcomes according to performance status, frailty and comorbidity.

• Post-progression therapy and healthcare-resource utilization.

• Sensitivity analyses addressing differential treatment initiation.

• Long-term survival and the possible emergence of a durable survival tail.

The broad label may be clinically reasonable, but equal effectiveness across the label should not be assumed before these data become available.

For Payers and HTA Bodies

At a wholesale acquisition cost of USD 39,800 per 30-day supply, the estimated gross acquisition cost over the 6.2-month median treatment duration is approximately USD 246,760 per patient.

The economic question is not whether the survival benefit is meaningful. It is whether the additional health generated exceeds the health displaced by that expenditure.

Payers should avoid applying one cost-effectiveness estimate to the entire label. At least three populations require separate analysis:

• Previously treated RAS G12-mutated disease.

• Previously treated non-G12 or RAS-unidentified disease.

• Treatment-naive patients considered unsuitable for multiagent therapy.

The first population has the strongest expected clinical and economic value. The other two carry substantially greater uncertainty.

Although the label does not require companion testing, comprehensive tumor profiling may remain economically efficient. Testing costs are small relative to several months of potentially ineffective treatment and may identify alternative actionable drivers.

Coverage strategies could include:

• Preferential evidence-based positioning after previous systemic treatment.

• Continued molecular profiling without making RAS testing an absolute access barrier.

• Evidence-development requirements for underrepresented populations.

• Outcomes-based agreements linked to treatment persistence, progression or survival.

• Price negotiations reflecting the absence of mature mean-survival and QALY estimates.

• Separate budget-impact scenarios for current use and earlier-line expansion.

The pivotal economic variable will be the net price after rebates, not WAC. Gross-to-net adjustments, treatment duration and real-world dose intensity will determine whether the commercial price remains compatible with conventional cost-effectiveness thresholds.

For Biopharmaceutical CEOs and Corporate Strategists

Revolution Medicines illustrates how a platform company can move from scientific differentiation to commercial validation. The tri-complex strategy has converted active RAS from a historically difficult target into a therapeutically actionable one.

The approval validates more than daraxonrasib. It provides support for a broader portfolio that includes G12D-, G12C- and G12V-selective inhibitors. Nevertheless, platform validation should not be confused with validation of every compound or indication.

The principal strategic opportunities are:

• Establishing RASONQUE as the preferred treatment after previous systemic therapy.

• Expanding daraxonrasib into first-line and adjuvant pancreatic cancer.

• Extending the franchise into non-small cell lung and colorectal cancers.

• Combining multi-selective and mutation-selective inhibitors to delay resistance.

• Using regional partnerships to expand internationally without building every commercial function internally.

• Developing next-generation agents against acquired resistance.

The central corporate risk is correlated concentration. Daraxonrasib is the only approved product, while most of the pipeline depends on the same RAS(ON) biological thesis. Resistance, class toxicity, intellectual-property disputes or manufacturing problems could affect several assets simultaneously.

Management must therefore demonstrate that the platform can deliver:

• Independent clinical success across multiple molecules.

• Differentiation between multi-selective and mutation-selective strategies.

• Combinations that improve durability without intolerable overlapping toxicity.

• Scalable manufacturing and reliable global supply.

• Commercial adoption that is not dependent solely on label breadth.

• Evidence supporting use beyond the original RAS G12 population.

The broad indication creates commercial opportunity but also increases the company’s evidence burden. If physicians and payers restrict real-world use to the best-supported subgroup, the practical market may be narrower than the regulatory label suggests.

For Investors

The approval substantially reduces clinical and regulatory risk but increases the importance of execution metrics. Future valuation should no longer depend primarily on whether daraxonrasib can reach the market. It should depend on how successfully the company monetizes the approval and converts it into a durable franchise.

Key commercial indicators include:

• Prescription and new-patient-start growth.

• Payer coverage and prior-authorization restrictions.

• Gross-to-net price development.

• Median real-world treatment duration.

• Dose-reduction and discontinuation rates.

• Adoption in academic versus community oncology.

• Use according to RAS subtype and treatment line.

• Uptake among patients considered ineligible for multiagent therapy.

• Conversion of expanded-access experience into reimbursed demand.

Revolution Medicines reported approximately USD 3.9 billion in cash and investments at June 30, 2026, providing substantial development and launch capacity. However, full-year operating-expense guidance of USD 2.1–2.2 billion indicates an exceptionally high expenditure rate.

The balance sheet should therefore be interpreted as well funded but not capital-insensitive. Investors must monitor:

• Commercial revenue relative to launch expenditure.

• Continued equity dilution.

• Potential conversion of the USD 500 million convertible notes.

• Royalty obligations affecting future product economics.

• Development spending across simultaneous Phase 3 programs.

• Dependence on additional financing if revenue ramps more slowly than expected.

Royalty Pharma financing reduced near-term funding risk but transferred part of future economics. The relevant valuation metric is therefore not gross RASONQUE revenue alone, but revenue remaining after rebates, distribution costs, royalties, commercialization expenses and continued development investment.

Competitive Timing

Revolution Medicines currently holds a meaningful first-mover advantage. No other approved therapy offers the same combination of oral administration, broad RAS targeting and randomized survival evidence in metastatic pancreatic cancer.

That advantage is time-limited.

Erasca’s ERAS-0015 is the closest broad RAS competitor in previously treated disease. Astellas is advancing setidegrasib into Phase 3 first-line G12D pancreatic cancer. Immuneering is pursuing a biomarker-independent first-line strategy, while Verastem and GenFleet are developing dual-state G12D inhibition. Eli Lilly and Bristol Myers Squibb possess greater global development and commercial resources.

The competitive question is not simply which molecule reaches approval next. It is which company establishes the strongest combination of:

• Overall survival.

• Durability.

• Tolerability.

• Ease of combination.

• Biomarker breadth.

• Earlier-line positioning.

• Net price and reimbursement.

• International commercial reach.

Revolution Medicines must use its regulatory lead to establish prescribing habits, payer relationships and real-world evidence before competing programs mature.

Critical Catalysts

The most consequential future events are:

• Initial U.S. launch performance and payer coverage.

• Real-world evidence in non-G12 and multiagent-ineligible patients.

• Longer-term RASolute 302 survival follow-up.

• First-line and adjuvant pancreatic cancer Phase 3 results.

• Daraxonrasib results in RAS-mutated non-small cell lung cancer.

• Confirmation or failure of zoldonrasib and elironrasib combinations.

• Evidence regarding resistance and next-generation RAS(ON) inhibitors.

• Regulatory decisions outside the United States.

• Comparative results from Erasca, Astellas, Immuneering and Verastem.

Strategic Bottom Line

Daraxonrasib has crossed the threshold from promising biotechnology asset to clinically validated commercial therapy. The survival benefit is sufficiently large to support rapid adoption in the evidence-backed population.

The next phase will be determined by whether Revolution Medicines can convert a broad regulatory label into sustainable economic value without allowing evidence uncertainty, payer resistance, high expenditure or platform concentration to erode its first-mover advantage.

For decision-makers, the priority is evidence segmentation. For CEOs, it is franchise execution and platform diversification. For investors, it is the conversion of clinical success into durable, risk-adjusted cash flow.

Conclusion

Daraxonrasib is both a therapeutic breakthrough and a test of how far regulatory and economic inference can extend beyond a pivotal population.

The Phase 3 evidence is unusually strong in previously treated RAS G12-mutated metastatic pancreatic adenocarcinoma. The endpoints were prospectively registered, multiplicity was controlled, and both progression-free and overall survival improved substantially. Safety, discontinuation, and patient-reported outcomes also favored the oral targeted strategy in clinically relevant ways.

The principal uncertainty lies at the edges of the indication. Evidence outside RAS G12 comes from only 41 heterogeneous patients and contains discordant PFS and OS signals. Treatment-naive frail patients ineligible for multiagent therapy were not directly randomized. Differential treatment initiation in the open-label study further requires sensitivity analyses separating the effect of treatment assignment from the effect of treatment received.

At USD 39,800 per month, the price transforms those evidentiary boundaries into opportunity-cost boundaries. Broad access may be clinically defensible, but the net health benefit of financing it will depend on net price, durability, quality-adjusted survival, displaced care, and the ability to concentrate treatment where expected benefit is greatest.

The appropriate institutional conclusion is neither that the approval was unsupported nor that the entire label carries equal evidentiary weight. It is more precise:

Daraxonrasib has established a new standard for previously treated RAS G12-mutated metastatic pancreatic cancer. Whether the same clinical and economic value extends across a biomarker-independent label and into treatment-naive patients unable to receive multiagent therapy remains an evidence-development question, not a settled conclusion.

References

Regulatory Approval and Prescribing Information

1. US Food and Drug Administration. FDA approves first-in-class targeted therapy for metastatic pancreatic cancer. Published August 26, 2026. Accessed September 3, 2026.

2. US Food and Drug Administration. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. Published August 26, 2026. Accessed September 3, 2026.

3. Revolution Medicines, Inc. RASONQUE™ (daraxonrasib) tablets: US Full Prescribing Information. Revised August 2026.

4. Revolution Medicines, Inc. US FDA approves Revolution Medicines’ RASONQUE™ (daraxonrasib). Published August 26, 2026. Accessed September 3, 2026.

Clinical Evidence

5. O’Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, et al.; RASolute 302 Trial Investigators. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. 2026;395(4):325–337. doi:10.1056/NEJMoa2605555.

6. ClinicalTrials.gov. NCT06625320: Phase 3 study of daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma—RASolute 302. US National Library of Medicine. Accessed September 3, 2026.

7. Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, et al.; RMC-6236-001 Investigators. Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. N Engl J Med. 2026;394(18):1790–1802. doi:10.1056/NEJMoa2505783.

8. ClinicalTrials.gov. NCT05379985: Study of RMC-6236 in patients with advanced solid tumors harboring specific RAS mutations. US National Library of Medicine. Accessed September 3, 2026.

9. Wolpin BM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib, a RAS(ON) multi-selective inhibitor, versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: primary and final analysis from RASolute 302. J Clin Oncol. 2026;44(17 suppl):LBA5. doi:10.1200/JCO.2026.44.17_suppl.LBA5.

10. Revolution Medicines, Inc. Daraxonrasib demonstrates unprecedented overall survival benefit in the pivotal Phase 3 RASolute 302 clinical trial. Published April 13, 2026. Accessed September 3, 2026.

11. Revolution Medicines, Inc. Revolution Medicines announces ASCO plenary presentation of Phase 3 RASolute 302 results. Published May 31, 2026. Accessed September 3, 2026.

Pharmacology and Translational Science

12. Cregg J, Edwards AV, Chang S, et al. Discovery of daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, noncovalent tri-complex inhibitor for the treatment of patients with multiple RAS-addicted cancers. J Med Chem. 2025;68(6):6064–6083. doi:10.1021/acs.jmedchem.4c02314.

13. Jiang J, Jiang L, Maldonato BJ, Wang Y, Holderfield M, Aronchik I, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2024;14:994–1017. doi:10.1158/2159-8290.CD-24-0027.

14. Aronchik I, et al. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Nat Med. Published online August 11, 2026. doi:10.1038/s41591-026-04537-w.

15. Revolution Medicines, Inc. RASONQUE™ (daraxonrasib): clinical pharmacology, pharmacokinetics, drug-interaction, safety, and nonclinical toxicology information. In: US Full Prescribing Information. Revised August 2026.

Pharmacoeconomics and Opportunity-Cost Methodology

16. Revolution Medicines, Inc. Current Report on Form 8-K: FDA approval and US wholesale acquisition cost of RASONQUE. US Securities and Exchange Commission. Filed August 26, 2026.

17. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093–1103. doi:10.1001/jama.2016.12195.

18. Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14. doi:10.1016/j.jval.2013.08.2291.

19. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-Effectiveness in Health and Medicine. 2nd ed. New York: Oxford University Press; 2017.

BBIU Methodological Note

The pharmacoeconomic estimates presented in this article are preliminary screening analyses developed by BBIU and are not published incremental cost-effectiveness ratios.

The estimated gross acquisition cost of approximately USD 246,760 per treated patient was calculated by multiplying the reported wholesale acquisition cost of USD 39,800 per 30-day supply by the 6.2-month median treatment duration reported in RASolute 302.

Similarly, the estimates of approximately USD 68,500 per additional median progression-free month and USD 455,600 per median life-year proxy are based on differences between reported medians. These calculations must not be interpreted as formal costs per progression-free life-year, life-year gained, or quality-adjusted life-year.

A complete economic evaluation would require individual patient-level or reconstructed survival data, mean rather than median survival, extrapolation of the complete survival curves, health-state utilities, treatment-emergent costs, subsequent therapies, administration costs, adverse-event costs, molecular-testing expenses, patient-time costs, discounts, rebates, and an explicit healthcare-system perspective.

Company, Financial Position, and Corporate Development

20. Revolution Medicines, Inc. Annual Report on Form 10-K for the year ended December 31, 2025. US Securities and Exchange Commission. Filed February 25, 2026.

21. Revolution Medicines, Inc. Revolution Medicines reports second-quarter 2026 financial results and corporate progress. Published August 5, 2026. Accessed September 3, 2026.

22. Revolution Medicines, Inc. 2026 Proxy Statement. Filed April 27, 2026.

23. Third Rock Ventures. Third Rock Ventures launches Revolution Medicines with a USD 45 million Series A financing. Published February 4, 2015. Accessed September 3, 2026.

24. Revolution Medicines, Inc. Revolution Medicines acquires Warp Drive Bio to expand its drug-discovery platform and oncology pipeline. Published October 16, 2018. Accessed September 3, 2026.

25. Revolution Medicines, Inc. Revolution Medicines announces pricing of its initial public offering. Published February 12, 2020. Accessed September 3, 2026.

26. Revolution Medicines, Inc. Revolution Medicines completes acquisition of EQRx. Published November 9, 2023. Accessed September 3, 2026.

27. Revolution Medicines, Inc.; BeOne Medicines. Clinical development and commercialization collaboration for RAS(ON) inhibitors in selected Asian markets. Published August 10, 2026. Accessed September 3, 2026.

Current Therapeutic Landscape

28. US Food and Drug Administration. FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma. Published February 13, 2024.

29. US Food and Drug Administration. FDA grants accelerated approval to zenocutuzumab-zbco for NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma. Published December 4, 2024.

30. US Food and Drug Administration. LYNPARZA® (olaparib): prescribing information. 2019.

31. US Food and Drug Administration. FDA approves pembrolizumab for adults and children with tumor mutational burden-high solid tumors. Published June 16, 2020.

Competitive Pipeline

32. Erasca, Inc. Updated preliminary Phase 1 data and development strategy for the pan-RAS molecular glue ERAS-0015. Published July 13, 2026. Accessed September 3, 2026.

33. Astellas Pharma Inc. Astellas doses first patient in Phase 3 study of setidegrasib for KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma. Published April 15, 2026. Accessed September 3, 2026.

34. Immuneering Corporation. First patient dosed in the pivotal Phase 3 MAPKeeper 301 study of atebimetinib in metastatic pancreatic cancer. Published June 11, 2026. Accessed September 3, 2026.

35. Verastem Oncology. First patient dosed in the registration-directed Phase 2 TARGET-D 201 study of VS-7375. Published June 16, 2026. Accessed September 3, 2026.

36. ClinicalTrials.gov. NCT06607185: clinical study of LY4066434 in participants with KRAS-mutant advanced solid tumors. US National Library of Medicine. Accessed September 3, 2026.

37. Bristol Myers Squibb. Bristol Myers Squibb strengthens and diversifies its oncology portfolio through the acquisition of Mirati Therapeutics. Published October 8, 2023. Accessed September 3, 2026.